India: Vivimed Labs bags $7.5m additional investment from OrbiMed Asia

Pharmaceuticals firm Vivimed Labs has received an additional investment of $7.5 million from healthcare investment firm OrbiMed Asia in its subsidiary Vivimed Labs (Mascarene).

Continue reading this story with a subscription to DealStreetAsia.


Should your colleagues be reading this article too? Contact us for corporate subscriptions at